In plain terms

The claim being assessed: Transient partial cellular reprogramming improves clinical healthspan in human adults.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The preregistered adult-human clinical-healthspan primary remains Γ with Moderate confidence. Direct original-body checks preserve real preclinical function and lifespan benefits while preventing cells, xenografts or remaining mouse lifespan from being presented as treated-human outcomes. A verified first-in-human ER-100 study and sponsor interim signal make this an active translational programme, not an established clinical result. The post-discovery nongating preclinical SC5 receives Ε within its exact experimental contexts.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Partial reprogramming has genuine preclinical functional benefits and an early human ocular trial; controlled human healthspan benefit and broad long-term safety remain unestablished.

Implications for health and treatment: The preregistered adult-human clinical-healthspan primary remains Γ with Moderate confidence. Direct original-body checks preserve real preclinical function and lifespan benefits while preventing cells, xenografts or remaining mouse lifespan from being presented as treated-human outcomes. A verified first-in-human ER-100 study and sponsor interim signal make this an active translational programme, not an established clinical result. The post-discovery nongating preclinical SC5 receives Ε within its exact experimental contexts.

Limits for individual care: 69 primary reports with 5 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 69 primary reports; claims: 75; verified: 75; unverified: 0. Verification is bounded attribution. Access: 5 partial-body and 64 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 1 correction applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Partial reprogramming has genuine preclinical functional benefits and an early human ocular trial; controlled human healthspan benefit and broad long-term safety remain unestablished.

Deciding experiment: A prospective exact-delivery adult-human trial measures independently masked objective clinical function and disease trajectory against a justified concurrent comparator, with prespecified exposure duration and full-recipient estimands. Analyze clock change independently of training/selection and test whether it predicts function beyond baseline factors. Use monitored dose/duration windows and long-term identity, inflammatory, delivery and tumor surveillance; no outcome-defined recipient exclusions.

Belief versus evidence: The preregistered adult-human clinical-healthspan primary remains Γ with Moderate confidence. Direct original-body checks preserve real preclinical function and lifespan benefits while preventing cells, xenografts or remaining mouse lifespan from being presented as treated-human outcomes. A verified first-in-human ER-100 study and sponsor interim signal make this an active translational programme, not an established clinical result. The post-discovery nongating preclinical SC5 receives Ε within its exact experimental contexts.

Best-supported rival: Molecular reset and function are partly separable (tournament rank 1; the nominal model ranks 2). Human fibroblast original PMID35390271 directly reports migration improvement varying independently of clock changes, while retaining genuine collagen and partial function. Retinal PMID33268865 establishes actual visual function with TET/TDG necessity and demethylation-alone insufficiency. Together these favor bounded output-specific reprogramming over clock reset as a universal clinical surrogate.

COMPETING MECHANISTIC MODELS

Rank 2: Reprogramming reverses causal aging processes (Γ). Changing epigenetic state repairs processes that can contribute to clinical aging. Actual local vision, graft force and preclinical lifespan outcomes support more than a purely descriptive marker story. No controlled adult-human healthspan or unique shared epigenetic mediator is established; identity and delivery effects remain.

Rank 1: Molecular reset and function are partly separable (Ε). Regimen-specific factors alter markers and selected tissue functions with incomplete coupling. Fibroblast clock/function dissociation, intervention-specific clocks and exact animal function show separable outputs. This does not explain every molecular mediator or prove clinical irrelevance of all clocks; genuine function is retained.

Rank 3: Selection and dedifferentiation shift measured age (Γ). Cell-state fractions, surviving cells and altered composition can contribute to lower measured age. Original cell sorting, temporary identity suppression, survivor-selected methylation and composition-sensitive clocks demonstrate concrete confounders. Matched culture controls and genuine mouse visual/muscle function prevent selection from explaining away the entire programme.

Rank 4: Delivery and expression windows govern function and hazard (Ε). Tissue, duration, factor combination and immune surveillance determine therapeutic benefit and loss-of-identity risk. Cyclic-versus-continuous fly effects, organ-exclusion rescue of mouse toxicity, local retinal benefit and AAV/pluripotency hazards map specific boundaries. Controlled windows do not establish universal human safety or a common endogenous cause of natural aging.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Transient partial cellular reprogramming improves clinical healthspan in human adults.

The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.

Selection: position 19 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T16:06:25.540258+00:00. Ranked editorial traffic priority rather than measured global popularity or a preset verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: Rubric 06 directly governs lifespan, healthspan, biomarkers, stress resistance and true-aging versus developmental effects. Rubric 03 governs epigenetic readouts and specificity against general identity/cell-cycle change. A delivered factor treatment can establish experimental therapeutic sufficiency in the system tested without demonstrating endogenous factor necessity. This does not relax the literal human scope or erase universal biomarker/overexpression limits on inference to endogenous aging. Registry/sponsor leads are separately attributed, not peer-reviewed original count or primary threshold credit.

This is an active experimental programme with real functional findings. Local OSK improves mouse vision after glaucoma-like injury; its original Methods use blinded optomotor assessment, and its Results require TET1/TET2/TDG while demethylation alone is insufficient. Function in a defined retinal context is beyond a marker-only story. It still does not show that all age-related decline is epigenetic, or that the same delivery safely improves clinical healthspan in human adults.

The very-old mouse study starts at 124 weeks and reports roughly 8.9 versus 18.5 weeks of remaining median life, together with better frailty. Its original Methods use buffer controls rather than a contemporaneous control AAV, with a historical AAV argument. Methylation is assessed in selected healthy terminal animals. Human keratinocytes are immortalized, puromycin-selected cultures. These exact methods matter: the paper is not a doubling of total mouse lifespan or a human healthspan trial.

Transient human-cell protocols reset selected markers and can change function. Sarkar and colleagues use human donors but put treated cells into immunocompromised mice; the direct force measurement is in mouse muscle recipients. Gill and colleagues use three donor fibroblast cultures, sort reprogramming intermediate states, observe temporary identity loss followed by recovery, and find migration benefits that vary independently of clocks. Some clocks and a telomere-clock estimate do not rejuvenate. These are meaningful cell studies with concrete translational and surrogate boundaries.

Other animal studies expand the contexts without eliminating them. Cyclic Drosophila OKSM and senolytic-peptide treatment improves survival whereas continuous expression is detrimental, with matched temperature cycling and no embryonic expression. Rat neural, mouse engram and disease-model experiments give genuine selected functional responses. Chemical cocktails alter human-cell hallmarks and worm survival. Distinct species, factors and outcomes prevent a simple count of papers from becoming independent clinical causal convergence.

Safety is a delivery/state question. Some transient or local protocols preserve examined identity and have short or selected follow-up without lesions. Other protocols temporarily suppress identity, leave problematic viral residues, cause acute liver/intestine failure during continuous induction, or reach full pluripotency with teratomas. Absence of c-Myc does not alone prevent full reprogramming in one AAV paradigm. These hazards are not proof that every partial treatment is unsafe, but they rule out a general safety guarantee based on a younger clock.

Clinical translation has begun. The official ER-100 registry records an unmasked nonrandomized phase-1 ocular study without posted results. A dated sponsor interim report describes three glaucoma recipients through day 56, with preliminary visual-field signals in two. This early uncontrolled, non-peer-reviewed signal is retained separately from the original-paper count and does not establish controlled human healthspan or durable safety.

Additional original-source checks outside the primary-report count

NCT07290244. Status: public clinical trial registry; excluded from 69 peer-reviewed original reports. Access: Original public API record retrieved and design, status and visual-function outcome fields actually presented.. Recruiting nonrandomized unmasked phase-1 ER-100 ocular study; estimated 18 participants, no posted Results section; primary completion estimated May 2027. Registry plans are not results, and an ocular safety-first study does not establish general human healthspan. This source is not included in the primary-report target or treated as a complete-paper audit.

ER100-SPONSOR-2026-10-08. Status: sponsor interim conference-data release; excluded from 69 peer-reviewed original reports. Access: Official webpage opened through web tool and original results/design lines 28–46 actually read.. Sponsor reports tolerability through day 56 in three glaucoma recipients and preliminary visual-field signals in two. Uncontrolled, open-label, sponsor-reported and not a peer-reviewed efficacy report; no durable function or lifetime safety demonstrated. This source is not included in the primary-report target or treated as a complete-paper audit.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The preregistered adult-human clinical-healthspan primary remains Γ with Moderate confidence. Direct original-body checks preserve real preclinical function and lifespan benefits while preventing cells, xenografts or remaining mouse lifespan from being presented as treated-human outcomes. A verified first-in-human ER-100 study and sponsor interim signal make this an active translational programme, not an established clinical result. The post-discovery nongating preclinical SC5 receives Ε within its exact experimental contexts. Sensitivities: weakest-link Γ; primary-subclaim Γ; scope-matched Γ.

Supplemental SC5 was added after source discovery at 2026-10-13T17:06:46.918073+00:00; it was not preregistered and does not gate the original primary aggregation. Preserve genuine preclinical functional/lifespan positives encountered during appraisal while keeping the fixed adult-human clinical-healthspan primary.

Decisive-perturbation inventory and causal tally

[1] AAV-OSK in very-old male mice improved remaining median survival and frailty, while immortalized human keratinocytes showed selected methylation-age changes. Actual M/R compare concurrent buffer controls, invoke historical AAV controls, select healthy survivors for methylation and selected immortalized cells; remaining life gain is not doubled total life or treated-human healthspan.

[2] Transient maturation-phase OSKM reset selected clocks, collagen and partial migration in three human-donor fibroblast cultures. Actual M/R show sorted reprogramming fractions, temporary identity loss then recovery, variable migration uncorrelated with clocks, clock-specific responses and no telomere-clock rejuvenation; no adult-human clinical trial.

[4] Actual Drosophila M/R show cyclic OKSM and senolytic-peptide interventions extending selected survival measures, whereas continuous OKSM shortened life. Adults without embryonic expression and temperature-matched controls support regimen-specific effects; the senolytic is a fly orthologous peptide, and mortality-model age-acceleration changes prevent simple universal aging-slowing or human translation.

[9] Transient factor mRNAs improved human-cell measures; treated old mouse muscle stem cells restored force in mouse graft recipients and human-cell grafts increased mouse bioluminescence. Actual M/R identify human donors but immunocompromised mouse recipients; force results and three-month no-lesion autopsy are not human functional-healthspan or lifetime safety results.

[19] Original retinal OSK M/R show functional vision benefit after mouse glaucoma injury and in a defined aging context, with Tet1/Tet2/TDG dependence. Demethylation alone was insufficient; oldest visual-acuity result was not positive, and clock feature selection included OSK/injury associations despite separate validation samples; differentiated human neuroblastoma cells are not clinical recipients.

[23] Cdkn2a-targeted OSK improved survival/selected function in progeroid and old wild-type mice, with no reported change in observed tumor incidence. Specific targeting and mouse follow-up are not proof of zero tumor risk across deliveries or human recipients; fibroblast inflammatory changes are not human healthspan.

[43] Immune-subtype comparisons showed clocks measure composition and intrinsic age; IntrinClock reduces composition dependence and responds to senescence/reprogramming. A corrected marker can improve measurement without proving intervention clinical benefit or safety; bulk-cell composition is a concrete alternative to years-reversed claims.

[46] Single-cell factor-subset screens restored youthful expression and transiently suppressed murine somatic identity with partly separable effects. Factor/identity heterogeneity is mechanistically useful but not adult-human clinical benefit; youthful expression does not ensure identity never changes or no tumor risk.

[55] NR in 20 older MCI adults increased NAD and selected clock measures changed, while cognition remained stable. Exploratory methylation and uncorrected CBF comparisons do not establish healthspan; drug exposure differs from reprogramming and illustrates marker/function dissociation.

[57] Technical clock-replicate noise reached several years and principal-component clock retraining improved reliability. Improved analytical repeatability is not clinical surrogate validation; apparent year reversal can reflect measurement noise rather than actual healthspan gain.

[61] Cyclic OSKM extended progeroid-mouse life and improved selected older wild-type injury/metabolic recovery outcomes. Premature-aging genotype and recovery endpoints differ from normal human clinical healthspan; full identity/tumor safety and unique epigenetic aging mediation are not established by this abstract.

[62] Transient four-factor induction in mice generated multi-organ teratomas and pluripotent/totipotent-like cells. This full-reprogramming paradigm identifies a real delivery/state hazard but does not prove every controlled partial OSK regimen causes tumors or quantify human risk.

[64] AAV factor delivery produced mouse teratomas and circulating iPS cells, including full reprogramming without c-Myc and detectable vector integration. Removing c-Myc alone did not prevent full plasticity in this regime; delivery, integration and expression duration differ from later controlled partial systems, so hazard cannot be generalized indiscriminately.

[65] Continuous OSKM caused mouse hepatic/intestinal dysfunction and early death; organ-exclusion strain design attenuated toxicity with molecular-age change. The actual continuous exposure differs from beneficial cyclic/tissue-targeted regimes; lower toxicity and markers are not proof of comprehensive safety or human healthspan.

Tally: 7 positive qualifying study units across scoped subclaims; 59 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Primary adult-human controlled healthspan positive tally is zero; preclinical SC5 exact systems retain their own positive study units. Multiple species/endpoints, platform follow-ups and public-dataset reanalyses are reports rather than automatically independent human causal lines. The ER-100 registry and sponsor interim release do not pad the 69 original-paper count or supply a controlled clinical-healthspan crossing.

Cap audit, precedence and Β/Γ/Δ boundary

Universal cap 3 limits ectopic-factor evidence offered as endogenous mechanism or broad human-aging proof; it does not deny a directly measured therapeutic sufficiency result in its specified animal recipient. Rubric-06 thresholds therefore bind SC5 actual-system function/lifespan, while marker, model-to-human and safety inference caps bind SC1–SC4. Human cultured cells and human-cell-to-mouse grafts remain their systems. No single weak association leg is re-capped over an independently complementary exact clinical set, because no such human set was assembled.

Universal six-cap audit: All six caps audited: in-vitro-only evidence cannot replace human recipients; prognostic associations do not establish intervention surrogacy; ectopic-factor results establish experimental sufficiency rather than endogenous human necessity; marker-only reset cannot substitute for function/safety; forced cell transfer establishes graft recipients rather than natural propagation; broad scope is not rescued by outcome-defined responders. Actual preclinical function is scored within SC5 under explicit scope/threshold precedence, rather than erased by a blanket marker/model cap.

Gamma hard-rule audit: All literal rubric-06 ROS/NAD/mitochondrial/senescence-marker-only, single-species/strain and biomarker-only rules were considered. Marker-only classes and extrapolation to human clinical aging retain Γ. The preclinical set includes different species and actual functional readouts, but does not create a shared human efficacy or safety set. Rubric-03 mark co-occurrence, imaging and reporter rules constrain epigenetic interpretation; none is silently used to erase verified local therapeutic function.

SC1 cap: “Mechanistic plausibility plus in vitro reconstitution or simplified cellular support caps at Γ.” Controlled partial reprogramming does change selected molecular and epigenetic measures. Human fibroblast studies, mouse tissues and factor screens show real experimental reset, with different clocks, factors and durations producing different changes. These mark-level and ectopic/cellular results do not establish an endogenous causal aging mechanism or clinical healthspan. Selected fractions, composition and training effects remain relevant; Γ describes mechanistic aging support, not a denial that markers changed.

SC2 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” No controlled prospective adult-human clinical-healthspan crossing was verified in the 69 examined original reports. Human donor-cell cultures, human-cell grafts into mice and preclinical function/survival results cannot replace human recipients. A separately verified ongoing ER-100 phase-1 ocular trial has a recent sponsor-reported uncontrolled short-term signal, which is retained as an early clinical lead but does not establish durable or controlled healthspan benefit. The credible preclinical programme supports Γ rather than narrative-only dismissal.

SC3 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Clocks can predict later risk and respond to some interventions, but predictive association and induced score change are not causal surrogate validation or tumor-risk prediction. Original fibroblast Results show migration changes that do not correlate with clock shifts and several clocks/telomere estimates that do not rejuvenate. Immune composition and technical noise demonstrably alter estimates. Retinal training uses injury/OSK-responsive features with independent test samples, supporting a local marker while requiring attention to circular interpretation. The broad prediction of functional benefit and safety is not established.

SC4 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” Exact cyclic, tissue-restricted and transient systems can preserve or reacquire tested identity and show limited follow-up without lesions, which is genuine safety-feasibility evidence. However, some cells temporarily lose identity, Sendai residues cause an adverse assay, continuous systemic induction can cause organ failure, and full reprogramming produces teratomas even without c-Myc in one AAV setting. These exposures differ, so they do not prove every partial system is dangerous. Nor do small short negative-safety observations establish sufficiently controlled tumor/identity risk across adult-human deliveries.

SC1 field-valid definition: “ - Endogenous degron of a condensate component with matched rescue, AND evidence that the specific condensate state (not generic protein loss) drives the phenotype - Locus-specific disruption of looping with locus-specific effect - Combinatorial histone-mark perturbation showing direct output dependence - Critically: specificity against cell-cycle collapse, global transcriptional collapse, and replication stress must be demonstrated” Positive full-scope result: no. Controlled partial reprogramming does change selected molecular and epigenetic measures. Human fibroblast studies, mouse tissues and factor screens show real experimental reset, with different clocks, factors and durations producing different changes. These mark-level and ectopic/cellular results do not establish an endogenous causal aging mechanism or clinical healthspan. Selected fractions, composition and training effects remain relevant; Γ describes mechanistic aging support, not a denial that markers changed.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. No controlled prospective adult-human clinical-healthspan crossing was verified in the 69 examined original reports. Human donor-cell cultures, human-cell grafts into mice and preclinical function/survival results cannot replace human recipients. A separately verified ongoing ER-100 phase-1 ocular trial has a recent sponsor-reported uncontrolled short-term signal, which is retained as an early clinical lead but does not establish durable or controlled healthspan benefit. The credible preclinical programme supports Γ rather than narrative-only dismissal.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Clocks can predict later risk and respond to some interventions, but predictive association and induced score change are not causal surrogate validation or tumor-risk prediction. Original fibroblast Results show migration changes that do not correlate with clock shifts and several clocks/telomere estimates that do not rejuvenate. Immune composition and technical noise demonstrably alter estimates. Retinal training uses injury/OSK-responsive features with independent test samples, supporting a local marker while requiring attention to circular interpretation. The broad prediction of functional benefit and safety is not established.

SC4 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Exact cyclic, tissue-restricted and transient systems can preserve or reacquire tested identity and show limited follow-up without lesions, which is genuine safety-feasibility evidence. However, some cells temporarily lose identity, Sendai residues cause an adverse assay, continuous systemic induction can cause organ failure, and full reprogramming produces teratomas even without c-Myc in one AAV setting. These exposures differ, so they do not prove every partial system is dangerous. Nor do small short negative-safety observations establish sufficiently controlled tumor/identity risk across adult-human deliveries.

SC5 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Supplemental SC5 explicitly added after discovery preserves real preclinical therapeutic sufficiency. Retinal OSK changes mouse vision with pathway controls and mapped age/readout limits; fly cycling changes survival relative to continuous expression, and additional rat/worm/mouse regimens have specified functional or survival positives. These are causally operative in experimentally defined contexts, supporting Ε for the preclinical proposition. They do not establish endogenous human aging necessity or higher independent convergence on a unique epigenetic-age mediator.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Factor-induced mark/state changes establish a direct measured phenomenon; higher endogenous mechanistic aging interpretation requires functional specificity rather than marker reset alone.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Human means adult recipients, not source donors, cultured human cells or human grafts into animals. A disease-specific objective function can be clinically relevant, but early uncontrolled sponsor signals need reliable causal estimation and durability.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Separate chronological prediction, clinical-risk prognosis and an intervention surrogate. Independent outcome validation and off-target/identity safety must be measured rather than inferred from a trained score.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Compare exact exposure windows and delivery sites; full pluripotency hazards do not automatically characterize controlled partial treatment, while short absence of tumors is not proof of zero risk.

SC5 applied rubric adaptation (distinct from the unchanged literal criterion): Therapeutic forced-factor sufficiency for a specified preclinical function/lifespan can cross within that actual recipient system. This is not endogenous propagation or natural human-aging causality; explicit mapped species/tissue/regimen/readout boundaries define Ε. The supplemental entry was registered after discovery and never gates SC2.

SC1 literal Γ hard rule: “In vitro phase separation alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “FRAP exchange dynamics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Histone mark co-occurrence alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Loop or contact enrichment alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Puncta presence alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Reporter-construct behavior alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

Upward threshold ladder

SC1 Δ: “Requires at least one endogenous perturbation showing the proposed feature contributes causally to the claimed output.” Satisfied: no. Use endogenous or precisely controlled locus/pathway interventions and rescue with cell-cycle/identity controls to link a specific epigenetic change to aging-relevant function rather than a clock score.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A controlled prospective human trial of exact partial delivery must improve independently assessed clinical function/disease trajectory with a durable full-population estimand and exposure-specific safety monitoring.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Prospectively show that induced clock change predicts independently measured function across distinct interventions and does not merely encode training targets, cell composition or selection; separately validate identity/tumor safety.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Map dose/duration/vehicle/tissue windows in preclinical and adult-human recipients with lineage tracing, delivery persistence, genomic stability and sufficiently long tumor and function follow-up.

SC5 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC5 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC5 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. Independently reproduce exact defined-regimen benefits and combine orthogonal mechanism/rescue, function and trajectory evidence excluding selection, injury-specific repair, developmental change and delivery artifacts.

Upper ladder: Controlled expression, withdrawal, tissue targeting and pathway rescue make higher rungs reachable for specified contexts. TET/TDG controls narrow retinal action but do not identify a universal human aging mediator. Mouse/rat/fly/worm successes use different factors, populations and outcomes and are not 69 independent causal lines. Human genetics on the exact delivered exposure, lifelong natural experiments and independently convergent human drug classes were considered; no qualifying human clinical set was examined. ER-100 is a genuine early clinical attempt, whose design and interim signal do not yet meet the primary causal gate.

Independence: No final/subclaim/model reaches Ζ. Functional regeneration and survival results are real but differing endpoints/regimens do not automatically exclude a shared delivery, selection, injury-response or clock-construction failure on the nominal human-healthspan mechanism. Shared parents, original secondary analyses and public dataset reanalyses are not new causal units. The clinical registry and sponsor report are the same ER-100 programme, not independent evidence.

Falsification and pitfalls

Universal marker-to-function coupling fails. Fibroblast migration did not correlate with clock changes, while clock-specific and NR cognition dissociations bound surrogate claims. No extra penalty is applied beyond the stated cap. Additional downgrade: False.

More reprogramming is not invariably more benefit. Continuous fly expression and continuous mouse organ exposure produce harm, whereas defined cyclic or local systems have positives. These are mapped context boundaries, not rejection of every partial protocol. Additional downgrade: False.

Confirmation by biomarker. Clock-years and transcript reset do not equal adult-human healthspan or tumor safety.

Donor/recipient system conflation. Human cells, centenarian donors and mouse xenografts are not treated adult-human recipients.

Intervention specificity assumed. Chemical cocktails, factor subsets, regeneration and TET dependence do not isolate a unique common epigenetic-age mediator.

Developmental benefit treated as aging reversal. Embryonic neural expansion and early-life models remain separate from adult aging interventions.

Scope fitted to outcome. Sorted successful cells, healthy terminal survivors and retrospective responders cannot define the nominal recipient population.

Replication confused with independence. Retinal follow-ups, mouse multiomics, shared diet trials and dataset reanalyses retain parents/platform overlap.

Safety absence generalized. Short no-lesion follow-up is not zero lifetime risk; full-reprogramming harms do not quantify every partial regimen.

Adversarial steelman: above, then below

Δ for adult-human healthspan could be defended by borrowing strong preclinical functional results or the new ER-100 interim human visual signal. The strongest version still needs reliable controlled clinical attribution and durability in actual human recipients; cell clocks, mouse grafts and an open-label three-person sponsor report do not supply that gate. Supplemental preclinical Ε is retained separately.

Β could be defended from clock-age correlation alone, but would discard direct factor/cocktail interventions, local functional recovery, survival and mechanism controls. These establish real partial-system and preclinical therapeutic action, making Γ more appropriate for unconfirmed human clinical translation.

Reject a human Δ upgrade because the required clinical gate is unverified, and reject association-only Β because controlled partial systems have mechanistic/function support. Retain Γ for SC2 and preserve Ε in explicitly post-discovery SC5. Neither provider enthusiasm nor a lack of a completed human trial is used to dismiss the entire experimental phenomenon.

Final score, causal direction and M/S/D

The preregistered adult-human clinical-healthspan primary remains Γ with Moderate confidence. Direct original-body checks preserve real preclinical function and lifespan benefits while preventing cells, xenografts or remaining mouse lifespan from being presented as treated-human outcomes. A verified first-in-human ER-100 study and sponsor interim signal make this an active translational programme, not an established clinical result. The post-discovery nongating preclinical SC5 receives Ε within its exact experimental contexts.

Applied factors precede marker and selected functional responses, so the intervention modifies established tissue/disease trajectories. Necessity, endogenous initiation and rate limitation across adult human aging are not shown; other metabolic or repair interventions can alter outcomes. The classification denotes a therapeutic modification role rather than declaring the Yamanaka factors an endogenous primary aging driver.

Momentum: Decisive work underway. ER-100 NCT07290244 is a named prospective human ocular intervention measuring safety and visual function. It is an early unmasked dose-escalation step toward the clinical boundary; controlled confirmation would still be required.

Stability: Uncertain. Pending ER-100 human function and longer safety observations could strengthen clinical translation or expose delivery/identity harms; current interim evidence cannot determine direction or durable causal efficacy. Registry completion dates are estimates, not promised publications.

Divergence: Contested. Do not manufacture a field-consensus score or belief gap from sponsor language, provider counts or editorial popularity. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A prospective exact-delivery adult-human trial measures independently masked objective clinical function and disease trajectory against a justified concurrent comparator, with prespecified exposure duration and full-recipient estimands. Analyze clock change independently of training/selection and test whether it predicts function beyond baseline factors. Use monitored dose/duration windows and long-term identity, inflammatory, delivery and tumor surveillance; no outcome-defined recipient exclusions.

Readout: Clinical function/disease outcome and durable safety primary; tissue identity, delivery persistence and adverse lesions measured separately; clock and other markers are mechanistic secondary endpoints.. Controls: Matched comparator, independent blinded function measurement, repeat baseline assessment/practice-effect control, prospective pathology/lineage and adverse-event review, locked clocks with independent outcome validation, all assigned/treated recipients retained.. Supporting: A credible durable human clinical function effect would cross the appropriate scoped first causal threshold; independent exact-context replication and mediator separation would move higher. Marker improvement alone is insufficient.. Falsifying: Clock changes without clinical function, loss of identity or adverse delivery consequences bound the specific human regimen; failure cannot be excused by selecting successful molecular responders..

KNOWLEDGE GAPS

Controlled durable adult-human clinical function rather than cell or animal transfer.

Independent clock-to-function intervention-surrogate validation and separate safety prediction.

Quantified exact-factor delivery/duration safety windows across relevant tissues and baseline diseases.

Mechanism-specific rescue distinguishing epigenetic repair from selection, dedifferentiation, altered metabolism and injury-specific regeneration.

Late-life versus developmental, sex, species and tissue generalization; remaining lifespan distinguished from total life.

Complete supplements, source-overlap reconstruction and long-term safety beyond the selected body passages.

REVIEWER NOTES

69 relevant original reports have actual abstract/status examination receipts, and five papers have selected original Methods/Results reading receipts. Human culture, preclinical intervention, original secondary-data analysis, clock methodology/prognosis and distinctly labeled comparator trials are represented, not 69 human reprogramming trials. Commentary, reviews and preprint-only records are excluded. Indexed corrections/status attach to parent sources; detailed correction contents were not independently audited. Supplemental SC5 has an actual post-discovery timestamp and explicitly does not gate SC2. A separate public registry and sponsor interim report are observed external leads, not completed clinical evidence or peer-reviewed count. Observed signed-in Consensus Pro browser output was read and reconciled in ten original-paper aspects plus a separate current ER-100 registry/sponsor comparison; categorical all-positive-preclinical wording was qualified, while marker/recipient and safety boundaries were preserved; no independent blinded review or complete-paper audit is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Observed Consensus correctly preserves the remaining-life denominator. Original Methods/Results show about 8.9 versus 18.5 remaining weeks after treatment at 124 weeks, with concurrent buffer controls and a historical control-AAV argument. This supports a real animal signal with delivery-control limits, not doubled total life or human efficacy. Original PMID38381405.

Provider summarizes older-donor keratinocyte clock reversal. Actual M/R identify an immortalized scalp-derived line, puromycin survivor selection and terminal healthy-animal selection for mouse methylation. These facts constrain selection and recipient interpretation; the human component is not an adult clinical intervention. Original PMID38381405.

Provider describes human-cell rejuvenation without erased identity, while its fuller wording notes no permanent loss. Actual M/R explicitly show temporary fibroblast identity suppression, sorting of intermediate states and later recovery. Retained final identity does not prove no intermediate dedifferentiation or universal safe control. Original PMID35390271.

Provider reports approximately thirty clock-years and collagen recovery. Actual Results retain those findings but show variable migration that did not correlate with clocks, multiple unresponsive clocks and no telomere-clock rejuvenation. This directly bounds clock-to-function surrogacy without discarding real partial cellular function. Original PMID35390271.

Provider correctly separates cell culture and grafts from systemic patients. Original Methods identify human donors and immunocompromised mouse recipients; actual force benefit is in mouse muscle, whereas human-cell graft benefit is assessed by mouse bioluminescence. No human strength or clinical-healthspan result is claimed. Original PMID32210226.

Provider gives TET-related regenerative benefit largely through reviews. Selected original Results confirm Tet1/Tet2/TDG dependence, but also show global Tet1 catalytic demethylation alone did not protect or regenerate. Actual vision improvement is retained while rejecting sufficiency of a younger methylation state alone. Original PMID33268865.

The provider emphasizes local retinal efficacy. Original Methods use blinded optomotor assessment and separate test samples, but clock-feature selection includes injury and OSK-response associations; original Results do not show the oldest visual-acuity benefit. Independent marker samples are useful but do not make the score a universal prospective clinical surrogate. Original PMID33268865.

Provider largely discusses rodent positives and does not resolve this requested original organism. Actual M/R establish Drosophila, adult expression without embryonic induction, temperature-matched controls, cyclic survival benefits and continuous-expression detriment. It is neither a mouse senolytic trial nor a human treatment, and its mortality modeling complicates a universal aging-rate reduction claim. Original PMID36287172.

Provider suggests omission of c-Myc reduces tumorigenesis, which may be valid in specific later systems. The examined original AAV abstract nevertheless reports full in vivo reprogramming without c-Myc, teratomas and vector integration. Omitting one oncogene is not a general safety certificate; full and controlled partial protocols remain distinct. Original PMID29985406.

Provider retains aged-cell-targeted OSK survival and wound-healing positives. The original abstract reports no changed observed tumor incidence in its mouse setting. That is useful bounded feasibility evidence rather than proof of absent neoplasia across deliveries, humans or longer follow-up. Original PMID39259812.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Partial Reprogramming and Human Aging

Selected publication milestones, not an exhaustive history or discovery priority claim.

2011 — Full pluripotent reprogramming resets aged-human-cell traits but entails identity loss and redifferentiation. Original PMID22056670.

2013 — In vivo factor induction demonstrates pluripotency and multi-organ teratoma hazards. Original PMID24025773.

2016 — Senescence and IL6 create a permissive mouse tissue state for reprogramming. Original PMID27884981.

2016 — Cyclic partial factors improve progeroid survival and selected old-wild-type recovery outcomes. Original PMID27984723.

2018 — AAV delivery achieves full reprogramming and teratomas even without c-Myc in a specific setting. Original PMID29985406.

2018 — PhenoAge develops clinical-risk prediction, which is distinct from intervention surrogate validation. Original PMID29676998.

2020 — Transient human-cell mRNAs improve cellular measures and graft function in mouse recipients. Original PMID32210226.

2020 — Retinal OSK provides actual mouse vision benefit and TET/TDG dependence with demethylation alone insufficient. Original PMID33268865.

2021 — A short diet/lifestyle pilot shifts a clock without establishing partial reprogramming or clinical years regained. Original PMID33844651.

2022 — A single OSKM cycle resets mouse multiomics, retaining the marker-versus-function boundary. Original PMID35235716.

2022 — Human fibroblasts regain identity after temporary suppression; migration varies independently of clock changes. Original PMID35390271.

2022 — Factor-subset screens separate youthful expression from partly separable somatic-identity suppression. Original PMID35690067.

2022 — Fly cyclic-versus-continuous expression maps survival benefit and regimen-dependent harms. Original PMID36287172.

2022 — Technical clock-replicate noise motivates more reliable measurement without supplying clinical surrogacy. Original PMID36277076.

2023 — Induced epigenomic-change models give mechanistic aging leads, with an attached erratum and forced-injury limits. Original PMID36638792.

2023 — Chemical cell cocktails reset selected transcript/compartment measures, providing cellular rather than human clinical evidence. Original PMID37437248.

2023 — Continuous systemic induction causes organ dysfunction; organ exclusions attenuate mouse toxicity. Original PMID38012287.

2023 — Retinal follow-up shows duration and withdrawal-dependent vision benefits within the same therapeutic platform. Original PMID38060815.

2024 — Very-old male mouse remaining-life and frailty positives require buffer-control and survivor-selection interpretation. Original PMID38381405.

2024 — Immune composition is explicitly separated from cell-intrinsic clock change. Original PMID39095531.

2024 — Aged-cell-directed OSK expands mouse functional/survival and observed-tumor feasibility evidence. Original PMID39259812.

2024 — Human cultured-MSC rejuvenation coexists with a viral-residue adverse assay. Original PMID39684245.

2025 — Old female rat cognition improves in a short neural gene-therapy context, with limited safety follow-up. Original PMID39037528.

2025 — Chemical reprogramming combines human-cell hallmarks with worm lifespan, preserving species separation. Original PMID40588563.

2026 — Engram-targeted OSK expands selected mouse cognitive contexts rather than human efficacy. Original PMID41672073.

2026 — Original public-dataset reanalysis identifies conserved CpGs without adding five new functional trials. Original PMID42647204.

Research gaps

Controlled durable adult-human clinical function rather than cell or animal transfer.

Independent clock-to-function intervention-surrogate validation and separate safety prediction.

Quantified exact-factor delivery/duration safety windows across relevant tissues and baseline diseases.

Mechanism-specific rescue distinguishing epigenetic repair from selection, dedifferentiation, altered metabolism and injury-specific regeneration.

Late-life versus developmental, sex, species and tissue generalization; remaining lifespan distinguished from total life.

Complete supplements, source-overlap reconstruction and long-term safety beyond the selected body passages.

Boundary experiment

A prospective exact-delivery adult-human trial measures independently masked objective clinical function and disease trajectory against a justified concurrent comparator, with prespecified exposure duration and full-recipient estimands. Analyze clock change independently of training/selection and test whether it predicts function beyond baseline factors. Use monitored dose/duration windows and long-term identity, inflammatory, delivery and tumor surveillance; no outcome-defined recipient exclusions.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks: all 69 REFERENCES PMIDs verified against PubMed metadata (69/69 resolved to the stated title, first author, journal and year; no retraction or expression-of-concern notices found in the retrieved records); 13 load-bearing claims spot-checked against the cited abstracts and the local registry record; scoring logic re-derived against references/hsef-framework.md and SKILL.md Steps 2–3 (hard caps, aggregation rule, Ζ independence basis, Β/Γ/Δ boundary, Momentum/Stability/Divergence artifacts).

Rejected findings (checked, no change): - Reference 3 (2026 vs PubMed 2025), 47 (2025 vs 2024), 66 (2023 vs 2024) and 69 (2018 vs 2017) — print/issue versus e-pub year differing by ±1 is within convention. - PubMed title/abstract fields that drop italicised gene names (Vitamin B12, p16High, OSK gene symbols in PMID 39259812) are PubMed rendering artifacts, not misstatements by the review. - Momentum "Decisive work underway" carries the required artifact: the named ER-100 trial NCT07290244, verified as recruiting, phase 1, non-randomized, unmasked, 18 estimated participants, primary completion estimated 2027-05, no posted results. - Divergence "Contested" with a null implied level is permitted by the framework's Divergence table where no single implied level applies; the basis field states why. - Aggregation: primary-subclaim on SC2 returns Γ, and weakest-link and scope-matched both also return Γ; SC5 (Ε) is explicitly scope-restricted to preclinical recipients and therefore cannot set a human-scoped headline. No change. - Numeric claims re-checked and correct: 124-week starting age and roughly 8.9 versus 18.5 weeks of remaining median life (PMID 38381405 reports +109% median remaining lifespan); ~30 years of transcriptome rejuvenation (PMID 35390271); TET1/TET2 requirement for OSK-induced vision recovery (PMID 33268865); full in vivo reprogramming without c-Myc with teratomas and vector integration (PMID 29985406); unchanged observed tumour incidence in naturally aged wild-type mice (PMID 39259812); 20 MCI participants with stable cognition and uncorrected CBF comparisons (PMID 37994989); up to 9 years of technical replicate noise (PMID 36277076).

Residual limitations: the ordering of the COMPETING MECHANISTIC MODELS list follows model ID rather than tournament rank, so the rank-1 model appears second; this is a renderer ordering artifact that the same builder produces in the sibling cases of this batch and was left in place rather than re-sequenced. Access depth is unchanged — 5 partial-body and 64 abstract/status examinations — so claims resting on Methods or Supplementary detail were verified only to the stated depth.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Macip CC, Hasan R, Hoznek V et al. Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice. Cellular reprogramming. 2024. PMID 38381405. DOI: 10.1089/cell.2023.0072. Access: full_text_partial. Study: PMID38381405.

2. Gill D, Parry A, Santos F et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. eLife. 2022. PMID 35390271. DOI: 10.7554/eLife.71624. Access: full_text_partial. Study: PMID35390271.

3. Zhang C, Bai Y, Yin Q et al. Hepatocyte-specific partial cellular reprogramming via selective OSK mRNA lipid nanoparticle attenuates liver fibrosis. Journal of controlled release : official journal of the Controlled Release Society. 2026. PMID 41443352. DOI: 10.1016/j.jconrel.2025.114569. Access: abstract_metadata. Study: PMID41443352.

4. Kaur P, Otgonbaatar A, Ramamoorthy A et al. Combining stem cell rejuvenation and senescence targeting to synergistically extend lifespan. Aging. 2022. PMID 36287172. DOI: 10.18632/aging.204347. Access: full_text_partial. Study: PMID36287172.

5. Tu H, Hosaka A, Hichiwa G et al. Rejuvenation of mesenchymal stromal cells via partial reprogramming enables scalable generation of transcriptionally diverse MSC libraries. Stem cell research & therapy. 2026. PMID 41862988. DOI: 10.1186/s13287-026-04977-8. Access: abstract_metadata. Study: PMID41862988.

6. Su YR, Gu SM, Liu YR et al. Partial cellular reprogramming stably restores the stemness of senescent epidermal stem cells. European review for medical and pharmacological sciences. 2023. PMID 37401274. DOI: 10.26355/eurrev_202306_32774. Access: abstract_metadata. Study: PMID37401274.

7. Kalies K, Knoepp K, Hehl L et al. Functional rejuvenation of endothelial cell aging by transient reprogramming. Basic research in cardiology. 2026. PMID 42360485. DOI: 10.1007/s00395-026-01192-7. Access: abstract_metadata. Study: PMID42360485.

8. Chenhao J, Lu H, Yasong L et al. Restoration of aged liver regeneration by youthful systemic factors via LTβ-driven hepatocyte reprogramming. Journal of hepatology. 2026. PMID 42772698. DOI: 10.1016/j.jhep.2026.08.036. Access: abstract_metadata. Study: PMID42772698.

9. Sarkar TJ, Quarta M, Mukherjee S et al. Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. Nature communications. 2020. PMID 32210226. DOI: 10.1038/s41467-020-15174-3. Access: full_text_partial. Study: PMID32210226.

10. Fitzgerald KN, Hodges R, Hanes D et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging. 2021. PMID 33844651. DOI: 10.18632/aging.202913. Access: abstract_metadata. Study: METHYLATION-LIFESTYLE-PILOT.

11. Yaskolka Meir A, Keller M, Hoffmann A et al. The effect of polyphenols on DNA methylation-assessed biological age attenuation: the DIRECT PLUS randomized controlled trial. BMC medicine. 2023. PMID 37743489. DOI: 10.1186/s12916-023-03067-3. Access: abstract_metadata. Study: PMID37743489.

12. Corley MJ, Dwaraka VB, Pang AP et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nature communications. 2026. PMID 42156721. DOI: 10.1038/s41467-026-72861-3. Access: abstract_metadata. Study: PMID42156721.

13. Villanueva JL, Vita AA, Zwickey H et al. Dietary associations with reduced epigenetic age: a secondary data analysis of the methylation diet and lifestyle study. Aging. 2025. PMID 40266024. DOI: 10.18632/aging.206240. Access: abstract_metadata. Study: METHYLATION-LIFESTYLE-PILOT.

14. Fiorito G, Caini S, Palli D et al. DNA methylation-based biomarkers of aging were slowed down in a two-year diet and physical activity intervention trial: the DAMA study. Aging cell. 2021. PMID 34535961. DOI: 10.1111/acel.13439. Access: abstract_metadata. Study: PMID34535961.

15. Horvath S, Zoller JA, Haghani A et al. DNA methylation age analysis of rapamycin in common marmosets. GeroScience. 2021. PMID 34482522. DOI: 10.1007/s11357-021-00438-7. Access: abstract_metadata. Study: PMID34482522.

16. Corley MJ, Watanabe M, Pang APS et al. Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2026. PMID 40576558. DOI: 10.1093/cid/ciaf247. Access: abstract_metadata. Study: PMID40576558.

17. Fuentealba M, Kiprov D, Schneider K et al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Aging cell. 2025. PMID 40424097. DOI: 10.1111/acel.70103. Access: abstract_metadata. Study: PMID40424097.

18. Borsky P, Holmannova D, Parova H et al. Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial). Scientific reports. 2025. PMID 40592961. DOI: 10.1038/s41598-025-05396-0. Access: abstract_metadata. Study: PMID40592961.

19. Lu Y, Brommer B, Tian X et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020. PMID 33268865. DOI: 10.1038/s41586-020-2975-4. Access: full_text_partial. Study: RETINAL-OSK-PLATFORM.

20. Yang JH, Hayano M, Griffin PT et al. Loss of epigenetic information as a cause of mammalian aging. Cell. 2023. PMID 36638792. DOI: 10.1016/j.cell.2022.12.027. Access: abstract_metadata. Study: PMID36638792.

21. Yang JH, Petty CA, Dixon-McDougall T et al. Chemically induced reprogramming to reverse cellular aging. Aging. 2023. PMID 37437248. DOI: 10.18632/aging.204896. Access: abstract_metadata. Study: PMID37437248.

22. Lu JY, Tu WB, Li R et al. Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming. Cell. 2025. PMID 40816266. DOI: 10.1016/j.cell.2025.07.031. Access: abstract_metadata. Study: PMID40816266.

23. Sahu SK, Reddy P, Lu J et al. Targeted partial reprogramming of age-associated cell states improves markers of health in mouse models of aging. Science translational medicine. 2024. PMID 39259812. DOI: 10.1126/scitranslmed.adg1777. Access: abstract_metadata. Study: PMID39259812.

24. Alvarez-Kuglen M, Ninomiya K, Qin H et al. ImAge quantitates aging and rejuvenation. Nature aging. 2024. PMID 39210148. DOI: 10.1038/s43587-024-00685-1. Access: abstract_metadata. Study: PMID39210148.

25. Xu L, Ramirez-Matias J, Hauptschein M et al. Restoration of neuronal progenitors by partial reprogramming in the aged neurogenic niche. Nature aging. 2024. PMID 38553564. DOI: 10.1038/s43587-024-00594-3. Access: abstract_metadata. Study: PMID38553564.

26. Kato C, Zheng J, Quang C et al. Sex-specific longitudinal reversal of aging in old frail mice. Aging. 2025. PMID 40848270. DOI: 10.18632/aging.206304. Access: abstract_metadata. Study: PMID40848270.

27. Kovatcheva M, Melendez E, Chondronasiou D et al. Vitamin B12 is a limiting factor for induced cellular plasticity and tissue repair. Nature metabolism. 2023. PMID 37973897. DOI: 10.1038/s42255-023-00916-6. Access: abstract_metadata. Study: PMID37973897.

28. Kim J, Hwang Y, Kim S et al. Electromagnetic field-inducible in vivo gene switch for remote spatiotemporal control of gene expression. Cell. 2026. PMID 41985457. DOI: 10.1016/j.cell.2026.03.029. Access: abstract_metadata. Study: PMID41985457.

29. Karg MM, Lu YR, Refaian N et al. Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma. Cellular reprogramming. 2023. PMID 38060815. DOI: 10.1089/cell.2023.0074. Access: abstract_metadata. Study: RETINAL-OSK-PLATFORM.

30. Browder KC, Reddy P, Yamamoto M et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature aging. 2022. PMID 37118377. DOI: 10.1038/s43587-022-00183-2. Access: abstract_metadata. Study: PMID37118377.

31. Sun ED, Zhou OY, Hauptschein M et al. Spatial transcriptomic clocks reveal cell proximity effects in brain ageing. Nature. 2025. PMID 39695234. DOI: 10.1038/s41586-024-08334-8. Access: abstract_metadata. Study: PMID39695234.

32. Drake SS, Mohammadnia A, Zaman A et al. Cellular rejuvenation protects neurons from inflammation-mediated cell death. Cell reports. 2025. PMID 39937646. DOI: 10.1016/j.celrep.2025.115298. Access: abstract_metadata. Study: PMID39937646.

33. Berdugo-Vega G, Sierra C, Astori S et al. Cognitive rejuvenation through partial reprogramming of engram cells. Neuron. 2026. PMID 41672073. DOI: 10.1016/j.neuron.2025.11.028. Access: abstract_metadata. Study: PMID41672073.

34. Schoenfeldt L, Paine PT, Picó S et al. Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan. EMBO molecular medicine. 2025. PMID 40588563. DOI: 10.1038/s44321-025-00265-9. Access: abstract_metadata. Study: PMID40588563.

35. Adelman ER, Huang HT, Roisman A et al. Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Cancer discovery. 2019. PMID 31085557. DOI: 10.1158/2159-8290.CD-18-1474. Access: abstract_metadata. Study: PMID31085557.

36. Wang P, Wang R, Huo Y et al. Partial Reprogramming in Senescent Schwann Cells Enhances Peripheral Nerve Regeneration via Restoration of Stress Granule Homeostasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025. PMID 40899516. DOI: 10.1002/advs.202511019. Access: abstract_metadata. Study: PMID40899516.

37. Mosteiro L, Pantoja C, Alcazar N et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science (New York, N.Y.). 2016. PMID 27884981. DOI: 10.1126/science.aaf4445. Access: abstract_metadata. Study: SENESCENCE-OSKM-PLATFORM.

38. Grigorash BB, van Essen D, Liang G et al. p16High senescence restricts cellular plasticity during somatic cell reprogramming. Nature cell biology. 2023. PMID 37652981. DOI: 10.1038/s41556-023-01214-9. Access: abstract_metadata. Study: PMID37652981.

39. Chondronasiou D, Gill D, Mosteiro L et al. Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming. Aging cell. 2022. PMID 35235716. DOI: 10.1111/acel.13578. Access: abstract_metadata. Study: PMID35235716.

40. Galán-Ganga M, Rodríguez-Navarro I, Zaballa S et al. Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease. Molecular biomedicine. 2026. PMID 42268557. DOI: 10.1186/s43556-026-00481-w. Access: abstract_metadata. Study: PMID42268557.

41. Cheng F, Wang C, Ji Y et al. Partial reprogramming strategy for intervertebral disc rejuvenation by activating energy switch. Aging cell. 2022. PMID 35266272. DOI: 10.1111/acel.13577. Access: abstract_metadata. Study: PMID35266272.

42. Găitănaru EC, Popescu RG, Stroe AA et al. Conserved Partial Reprogramming Effects on the Methylome. Epigenomes. 2026. PMID 42647204. DOI: 10.3390/epigenomes10030055. Access: abstract_metadata. Study: PMID42647204.

43. Tomusiak A, Floro A, Tiwari R et al. Development of an epigenetic clock resistant to changes in immune cell composition. Communications biology. 2024. PMID 39095531. DOI: 10.1038/s42003-024-06609-4. Access: abstract_metadata. Study: PMID39095531.

44. Zheng J, Ke J, Wu S et al. Epigenetic reprogramming periosteum promotes aging critical segmental bone defect repair via methylation remodeling. Bioactive materials. 2026. PMID 41953144. DOI: 10.1016/j.bioactmat.2026.03.036. Access: abstract_metadata. Study: PMID41953144.

45. Ivanova J, Shorokhova M, Pugovkina N et al. Partial Reprogramming Exerts a Rejuvenating Effect on Human Mesenchymal Stem Cells That Underwent Replicative Senescence in Culture. International journal of molecular sciences. 2024. PMID 39684245. DOI: 10.3390/ijms252312533. Access: abstract_metadata. Study: PMID39684245.

46. Roux AE, Zhang C, Paw J et al. Diverse partial reprogramming strategies restore youthful gene expression and transiently suppress cell identity. Cell systems. 2022. PMID 35690067. DOI: 10.1016/j.cels.2022.05.002. Access: abstract_metadata. Study: PMID35690067.

47. Horvath S, Lacunza E, Mallat MC et al. Cognitive rejuvenation in old rats by hippocampal OSKM gene therapy. GeroScience. 2025. PMID 39037528. DOI: 10.1007/s11357-024-01269-y. Access: abstract_metadata. Study: PMID39037528.

48. Picó S, Vílchez-Acosta A, Agostinho de Sousa J et al. Comparative analysis of mouse strains for in vivo induction of reprogramming factors. Cell reports. 2025. PMID 40560729. DOI: 10.1016/j.celrep.2025.115879. Access: abstract_metadata. Study: PMID40560729.

49. Chondronasiou D, Martínez de Villarreal J, Melendez E et al. Deciphering the roadmap of in vivo reprogramming toward pluripotency. Stem cell reports. 2022. PMID 36270281. DOI: 10.1016/j.stemcr.2022.09.009. Access: abstract_metadata. Study: PMID36270281.

50. Camacho O, Koldobskiy MA, Reddy P et al. Convergence of aging- and rejuvenation-related epigenetic alterations on PRC2 targets. Molecular systems biology. 2026. PMID 41667860. DOI: 10.1038/s44320-026-00195-9. Access: abstract_metadata. Study: PMID41667860.

51. Wan MD, Liu XX, Wan TF et al. Epigenetic brain reprogramming rejuvenates neuro-immune circuits to reverse Alzheimer's disease pathology and systemic bone loss. Journal of neuroinflammation. 2026. PMID 42210397. DOI: 10.1186/s12974-026-03854-8. Access: abstract_metadata. Study: PMID42210397.

52. Akakura S, Tabibzadeh S. AKG-TET axis is central to senescence plasticity. iScience. 2026. PMID 41497192. DOI: 10.1016/j.isci.2025.114298. Access: abstract_metadata. Study: PMID41497192.

53. Kim C, Nam SH, Park JH et al. Mesenchymal stem cell derived extracellular vesicles reverses neural aging via OSKM modulation. Cell communication and signaling : CCS. 2025. PMID 41162985. DOI: 10.1186/s12964-025-02469-5. Access: abstract_metadata. Study: PMID41162985.

54. Levine ME, Lu AT, Quach A et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018. PMID 29676998. DOI: 10.18632/aging.101414. Access: abstract_metadata. Study: PMID29676998.

55. Orr ME, Kotkowski E, Ramirez P et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024. PMID 37994989. DOI: 10.1007/s11357-023-00999-9. Access: abstract_metadata. Study: PMID37994989.

56. Srivatsa S, Rice N, Pike JR et al. Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA. Journal of the American Heart Association. 2025. PMID 41368835. DOI: 10.1161/JAHA.125.044946. Access: abstract_metadata. Study: PMID41368835.

57. Higgins-Chen AT, Thrush KL, Wang Y et al. A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. Nature aging. 2022. PMID 36277076. DOI: 10.1038/s43587-022-00248-2. Access: abstract_metadata. Study: PMID36277076.

58. Komaki S, Ohmomo H, Hachiya T et al. Evaluation of short-term epigenetic age fluctuation. Clinical epigenetics. 2022. PMID 35681206. DOI: 10.1186/s13148-022-01293-9. Access: abstract_metadata. Study: PMID35681206.

59. Dwaraka VB, Aronica L, Carreras-Gallo N et al. Unveiling the epigenetic impact of vegan vs. omnivorous diets on aging: insights from the Twins Nutrition Study (TwiNS). BMC medicine. 2024. PMID 39069614. DOI: 10.1186/s12916-024-03513-w. Access: abstract_metadata. Study: PMID39069614.

60. Fuentealba M, Rouch L, Guyonnet S et al. A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors. Nature aging. 2025. PMID 40467932. DOI: 10.1038/s43587-025-00883-5. Access: abstract_metadata. Study: PMID40467932.

61. Ocampo A, Reddy P, Martinez-Redondo P et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell. 2016. PMID 27984723. DOI: 10.1016/j.cell.2016.11.052. Access: abstract_metadata. Study: PMID27984723.

62. Abad M, Mosteiro L, Pantoja C et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013. PMID 24025773. DOI: 10.1038/nature12586. Access: abstract_metadata. Study: PMID24025773.

63. Lapasset L, Milhavet O, Prieur A et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes & development. 2011. PMID 22056670. DOI: 10.1101/gad.173922.111. Access: abstract_metadata. Study: PMID22056670.

64. Senís E, Mosteiro L, Wilkening S et al. AAVvector-mediated in vivo reprogramming into pluripotency. Nature communications. 2018. PMID 29985406. DOI: 10.1038/s41467-018-05059-x. Access: abstract_metadata. Study: PMID29985406.

65. Parras A, Vílchez-Acosta A, Desdín-Micó G et al. In vivo reprogramming leads to premature death linked to hepatic and intestinal failure. Nature aging. 2023. PMID 38012287. DOI: 10.1038/s43587-023-00528-5. Access: abstract_metadata. Study: PMID38012287.

66. Paine PT, Rechsteiner C, Morandini F et al. Initiation phase cellular reprogramming ameliorates DNA damage in the ERCC1 mouse model of premature aging. Frontiers in aging. 2023. PMID 38322248. DOI: 10.3389/fragi.2023.1323194. Access: abstract_metadata. Study: PMID38322248.

67. Shen YR, Zaballa S, Bech X et al. Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming. Cell stem cell. 2024. PMID 39426381. DOI: 10.1016/j.stem.2024.09.013. Access: abstract_metadata. Study: PMID39426381.

68. Melendez E, Chondronasiou D, Mosteiro L et al. Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development (Cambridge, England). 2022. PMID 35420133. DOI: 10.1242/dev.200361. Access: abstract_metadata. Study: PMID35420133.

69. Mosteiro L, Pantoja C, de Martino A et al. Senescence promotes in vivo reprogramming through p16INK4a and IL-6. Aging cell. 2018. PMID 29280266. DOI: 10.1111/acel.12711. Access: abstract_metadata. Study: SENESCENCE-OSKM-PLATFORM.

Source-specific evidence cards

[1] Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice.

Shows: AAV-OSK in very-old male mice improved remaining median survival and frailty, while immortalized human keratinocytes showed selected methylation-age changes.

Does not show: Actual M/R compare concurrent buffer controls, invoke historical AAV controls, select healthy survivors for methylation and selected immortalized cells; remaining life gain is not doubled total life or treated-human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Materials and Methods:paragraph1, 1:Materials and Methods:paragraph2, 1:Materials and Methods:paragraph3, 1:Materials and Methods:paragraph4, 1:Materials and Methods:paragraph7, 1:Materials and Methods:paragraph8, 2:Results:paragraph1, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph10, 2:Results:paragraph11. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4, SC5.

[2] Multi-omic rejuvenation of human cells by maturation phase transient reprogramming.

Shows: Transient maturation-phase OSKM reset selected clocks, collagen and partial migration in three human-donor fibroblast cultures.

Does not show: Actual M/R show sorted reprogramming fractions, temporary identity loss then recovery, variable migration uncorrelated with clocks, clock-specific responses and no telomere-clock rejuvenation; no adult-human clinical trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph4, 1:Results:paragraph7, 1:Results:paragraph17, 1:Results:paragraph22, 1:Results:paragraph23, 3:Materials and methods:paragraph1, 3:Materials and methods:paragraph2, 3:Materials and methods:paragraph14, 3:Materials and methods:paragraph16. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

[3] Hepatocyte-specific partial cellular reprogramming via selective OSK mRNA lipid nanoparticle attenuates liver fibrosis.

Shows: Hepatocyte-selective OSK mRNA nanoparticles reduced fibrogenic signaling and fibrosis in CCl4-injured mice.

Does not show: Forced injury, progenitor-like hepatocytes and delivery-specific preclinical safety do not establish systemic healthy-human benefit, stable identity or lifetime tumor absence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[4] Combining stem cell rejuvenation and senescence targeting to synergistically extend lifespan.

Shows: Actual Drosophila M/R show cyclic OKSM and senolytic-peptide interventions extending selected survival measures, whereas continuous OKSM shortened life.

Does not show: Adults without embryonic expression and temperature-matched controls support regimen-specific effects; the senolytic is a fly orthologous peptide, and mortality-model age-acceleration changes prevent simple universal aging-slowing or human translation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph4, 1:RESULTS:paragraph13, 1:RESULTS:paragraph17, 1:RESULTS:paragraph21, 1:RESULTS:paragraph22, 3:MATERIALS AND METHODS:paragraph2, 3:MATERIALS AND METHODS:paragraph19, 3:MATERIALS AND METHODS:paragraph22. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[5] Rejuvenation of mesenchymal stromal cells via partial reprogramming enables scalable generation of transcriptionally diverse MSC libraries.

Shows: Sendai-delivered hTERT/BMI1/SV40T in human MSCs prolonged proliferation and reset transcriptomic programs with normal examined karyotypes and retained differentiation.

Does not show: This distinct factor set and culture/manufacturing result is not a human treatment trial; normal karyotype does not prove absent oncogenic or residual-delivery risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[6] Partial cellular reprogramming stably restores the stemness of senescent epidermal stem cells.

Shows: Transient OSKM improved senescent epidermal-stem-cell proliferation, self-renewal and methylation measures with epithelial identity retained over short follow-up.

Does not show: Two-week maintenance and stem-cell markers are not human clinical healthspan or long-term tumor safety; proposed DNMT1 involvement needs necessary mediator tests.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[7] Functional rejuvenation of endothelial cell aging by transient reprogramming.

Shows: A pharmacological cocktail improved senescent endothelial-cell functions and short-term hind-limb perfusion in old mice.

Does not show: Cultured-cell and induced-ischemia outcomes differ from systemic aging; approved individual compounds do not establish this combination's clinical safety or partial-reprogramming specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[8] Restoration of aged liver regeneration by youthful systemic factors via LTβ-driven hepatocyte reprogramming.

Shows: Young circulation and LTBR-directed manipulations improved old-mouse liver regeneration with a parallel human graft-age association.

Does not show: A retrospective human transplantation association is not assigned partial reprogramming in adult recipients; parabiotic and injury-repair scopes and the different LTBR exposure remain distinct.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[9] Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells.

Shows: Transient factor mRNAs improved human-cell measures; treated old mouse muscle stem cells restored force in mouse graft recipients and human-cell grafts increased mouse bioluminescence.

Does not show: Actual M/R identify human donors but immunocompromised mouse recipients; force results and three-month no-lesion autopsy are not human functional-healthspan or lifetime safety results.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph6, 1:Results:paragraph15, 1:Results:paragraph17, 1:Results:paragraph18, 1:Results:paragraph19, 2:Methods:paragraph3, 2:Methods:paragraph4, 2:Methods:paragraph6, 2:Methods:paragraph35, 2:Methods:paragraph36. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4, SC5.

[10] Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial.

Shows: An eight-week 43-man lifestyle pilot reported a favorable saliva DNAmAge difference versus untreated controls.

Does not show: A lifestyle exposure is not partial cellular reprogramming; clock shifts do not demonstrate clinical years regained, and two indexed errata remain linked without detailed correction audit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID35907207; ErratumIn: PMID38488762. Subclaims: SC1, SC3, SC4.

[11] The effect of polyphenols on DNA methylation-assessed biological age attenuation: the DIRECT PLUS randomized controlled trial.

Shows: DIRECT PLUS found no between-assigned-diet differences in clock change, while adherence and selected polyphenol measures correlated with attenuation.

Does not show: Within-adherence associations and observed-versus-expected age differ from randomized-group effects; neither establishes reprogramming or clinical benefit from clock movement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[12] Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.

Shows: Exploratory posthoc semaglutide analysis in 84 HIV-lipohypertrophy adults reported changes across selected epigenetic clocks at 32 weeks.

Does not show: Epigenetic outcomes were not prespecified; drug, cohort, multiplicity and short duration cannot establish OSK clinical healthspan or clock-mediated benefit; earlier version is linked status, not another trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID40791720. Subclaims: SC1, SC3.

[13] Dietary associations with reduced epigenetic age: a secondary data analysis of the methylation diet and lifestyle study.

Shows: Secondary analysis of the small methylation-lifestyle study associated dietary components with clock change after selected adjustments.

Does not show: Shares the parent intervention and nonrandom achieved dietary intake; it does not supply independent causal marker validation or a reprogramming clinical trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[14] DNA methylation-based biomarkers of aging were slowed down in a two-year diet and physical activity intervention trial: the DAMA study.

Shows: DAMA factorial diet/activity assignment in 219 women altered selected DNAmGrimAge and epigenetic-mutation measures over two years.

Does not show: Changing an aging biomarker is not demonstrating clinical aging reversal, and diet/activity differ from cellular reprogramming.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[15] DNA methylation age analysis of rapamycin in common marmosets.

Shows: Marmoset clock development yielded age predictors but rapamycin intervention produced no significant blood epigenetic-age effect.

Does not show: A clock null does not establish absence of drug benefit; another exposure/species and blood compartment cannot validate human partial-reprogramming efficacy or safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[16] Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial.

Shows: A REPRIEVE substudy found no pitavastatin PCGrimAge difference but a selected DunedinPACE difference at 24 months.

Does not show: The parent clinical cardiovascular benefit and differing clock responses cannot prove a universal clock surrogate; statin exposure and a 99-person substudy are not OSK recipients.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[17] Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.

Shows: A 42-person plasma-exchange study reported selected multi-omic/clock improvements, with two adverse-event discontinuations.

Does not show: Entry-date-based assignment deserves scrutiny; exploratory biomarkers, IVIG and exchange regimens are not Yamanaka exposure, clinical healthspan or universally safe aging reversal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

[18] Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial).

Shows: A crossover plasmapheresis comparison altered circulating factors without significant clock rejuvenation and with selected clocks increasing.

Does not show: Different removal regimen and marker outcomes do not establish human healthspan improvement or reprogramming failure; safety and procedural context remain specific.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

[19] Reprogramming to recover youthful epigenetic information and restore vision.

Shows: Original retinal OSK M/R show functional vision benefit after mouse glaucoma injury and in a defined aging context, with Tet1/Tet2/TDG dependence.

Does not show: Demethylation alone was insufficient; oldest visual-acuity result was not positive, and clock feature selection included OSK/injury associations despite separate validation samples; differentiated human neuroblastoma cells are not clinical recipients.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 3:Regeneration requires DNA demethylation:paragraph0, 3:Regeneration requires DNA demethylation:paragraph1, 5:Recovery of vision in mice with glaucoma:paragraph0, 5:Recovery of vision in mice with glaucoma:paragraph1, 6:Restoration of vision in old mice:paragraph0, 6:Restoration of vision in old mice:paragraph1, 6:Restoration of vision in old mice:paragraph2, 8:Methods:paragraph0, 8:Methods:paragraph16, 8:Methods:paragraph21, 8:Methods:paragraph28, 8:Methods:paragraph34. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4, SC5.

[20] Loss of epigenetic information as a cause of mammalian aging.

Shows: Induced epigenomic-change experiments advanced mouse aging-like physiological and molecular measures, with OSK-reversible signatures.

Does not show: Forced DNA-repair/epigenomic injury does not establish natural human aging initiation or exclusively epigenetic mediation; an indexed erratum is retained without inventing its details.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID38428398. Subclaims: SC1, SC2, SC3, SC4.

[21] Chemically induced reprogramming to reverse cellular aging.

Shows: Six chemical cocktails improved human-cell transcriptomic aging and nucleocytoplasmic-compartment measures without reported loss of examined identity.

Does not show: Less-than-one-week cultured-cell readouts are not adult-human clinical benefit or long-term safety; assay-selected rejuvenation does not prove a unique anti-aging mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

[22] Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming.

Shows: Large cross-tissue expression analysis identified mesenchymal drift, and selected factor suppression/partial reprogramming reduced drift and aging signatures.

Does not show: Human disease-survival association plus cellular perturbation does not establish adult clinical treatment benefit, necessary drift mediation or independent patient-level validation of every tissue.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[23] Targeted partial reprogramming of age-associated cell states improves markers of health in mouse models of aging.

Shows: Cdkn2a-targeted OSK improved survival/selected function in progeroid and old wild-type mice, with no reported change in observed tumor incidence.

Does not show: Specific targeting and mouse follow-up are not proof of zero tumor risk across deliveries or human recipients; fibroblast inflammatory changes are not human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[24] ImAge quantitates aging and rejuvenation.

Shows: ImAge imaging captured mouse aging trajectories and intervention-associated changes, with locomotor correlations.

Does not show: An imaging marker-function correlation is not a prospectively validated surrogate for reprogramming clinical benefit or safety; linked earlier version and erratum do not add studies.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID37986947; ErratumIn: PMID40764433. Subclaims: SC1, SC3.

[25] Restoration of neuronal progenitors by partial reprogramming in the aged neurogenic niche.

Shows: Whole-body or niche-targeted partial reprogramming increased old-mouse neuroblast/new-neuron measures and altered aging signatures.

Does not show: Neurogenic output is not human cognition or clinical healthspan; cell proportion, proliferation and niche effects require distinctions from stable identity and long-term safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[26] Sex-specific longitudinal reversal of aging in old frail mice.

Shows: Oxytocin plus ALK5 inhibition improved old-frail male mouse function and survival, while female longevity benefit was absent.

Does not show: This different treatment demonstrates sex/context and acute-marker/durable-function limits, not a Yamanaka-factor causal crossing; remaining and total lifespan percentages differ and an erratum remains linked.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID41348538. Subclaims: SC2, SC3, SC4.

[27] Vitamin B12 is a limiting factor for induced cellular plasticity and tissue repair.

Shows: B12 supplementation increased OSKM reprogramming efficiency and improved repair, with H3K36me3 and metabolic links.

Does not show: Factor efficiency and colitis repair are not adult human healthspan or globally safe identity preservation; one-carbon/metabolic coeffects need separated mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[28] Electromagnetic field-inducible in vivo gene switch for remote spatiotemporal control of gene expression.

Shows: An EMF-controlled switch induced OSK in old mice and used mechanistic screening to identify activation dependencies.

Does not show: A controllable delivery platform is not verified human anti-aging efficacy or tumor-free lifetime safety; an indexed correction is attached and unrelated switch applications remain separate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID42372722. Subclaims: SC1, SC2, SC4.

[29] Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma.

Shows: Mouse glaucoma OSK follow-up reported sustained vision benefits, expression withdrawal kinetics and no examined retinal/body-weight adverse changes.

Does not show: Local retinal safety measures over the reported duration do not establish systemic or human safety; benefit diminished after withdrawal and shares the prior retinal OSK platform.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[30] In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice.

Shows: Longer physiological-aging mouse reprogramming regimens changed tissue/metabolic signatures and selected aging phenotypes with duration dependence.

Does not show: Regimen-specific observations do not establish human healthspan, isolated epigenetic-clock mediation or absence of all neoplasia; late-life versus developmental timing remains critical.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

[31] Spatial transcriptomic clocks reveal cell proximity effects in brain ageing.

Shows: A large spatial mouse-brain atlas derived clocks and detected cell-neighbor/intervention-associated aging patterns.

Does not show: Spatial proximity and clock-model effects are not necessary mediator tests or prospective adult-human clinical surrogate validation; atlas and reprogramming parents may overlap.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[32] Cellular rejuvenation protects neurons from inflammation-mediated cell death.

Shows: RGC OSK increased survival and visual acuity in EAE mice, alongside related neuronal signatures in MS patients.

Does not show: Human observational signatures are not treated patients; inflammation injury and local gene therapy do not establish generalized healthy-human aging or tumor safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID37873446. Subclaims: SC1, SC2, SC4.

[33] Cognitive rejuvenation through partial reprogramming of engram cells.

Shows: Engram-targeted OSK restored selected learning/memory measures and cellular/synaptic patterns in old/AD-model mice.

Does not show: Specific neural populations, disease models and behavioral paradigms are preclinical contexts; no adult-human healthspan or broad safe delivery follows automatically.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[34] Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan.

Shows: Chemical partial reprogramming improved aged-human-cell hallmarks and a two-compound regimen extended C. elegans lifespan/healthspan.

Does not show: Human cells and worms are not adult-human recipients; compound off-targets and different species limit a common specific reprogramming mediator inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4, SC5.

[35] Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia.

Shows: Human HSC aging altered enhancers/cancer pathways, and KLF6 reduction impaired differentiation with aging/leukemia-like signatures.

Does not show: This is endogenous disease-associated epigenetic change and a cellular perturbation, not therapeutic OSK rejuvenation; it illustrates identity/cancer alternatives without proving Yamanaka tumor risk in humans.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

[36] Partial Reprogramming in Senescent Schwann Cells Enhances Peripheral Nerve Regeneration via Restoration of Stress Granule Homeostasis.

Shows: Partial reprogramming improved aged-rat peripheral nerve repair and Schwann-cell stress-granule homeostasis.

Does not show: Specific nerve injury and a rat recipient are not generalized human healthspan; association and pathway-resetting need necessary mechanism controls before unique attribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[37] Tissue damage and senescence provide critical signals for cellular reprogramming in vivo.

Shows: Mouse OSKM produced neighboring senescence/reprogramming and genetic/pharmacological tests implicated Ink4a/Arf and IL6 in a permissive tissue state.

Does not show: Damage-associated and pluripotent reprogramming are not synonymous with safe partial rejuvenation; senescence can aid plasticity and complicate universal anti-senescence claims.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[38] p16High senescence restricts cellular plasticity during somatic cell reprogramming.

Shows: Removing p16-high cells altered reprogramming toward totipotent-like states and enabled selected old-mouse liver-marker responses.

Does not show: Extraembryonic plasticity and combined senescence depletion challenge blanket identity/safety claims; markers and combination exposure do not establish human healthspan or isolated OSKM benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[39] Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming.

Shows: One transient OSKM cycle shifted aged-mouse methylome, transcriptome and metabolome signatures toward younger configurations.

Does not show: Molecular reset alone does not demonstrate organismal lifespan/function or human clinical efficacy; tissue and timing differ from other regimen results.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[40] Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease.

Shows: Intermittent neuronal factors improved P301S-mouse behavior/synchrony with sex-dependent effects and candidate NMDAR-complex changes.

Does not show: A tauopathy model and candidate network mediator are not a clinical AD trial or human aging proof; sex/context and necessary signaling tests constrain generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[41] Partial reprogramming strategy for intervertebral disc rejuvenation by activating energy switch.

Shows: Short cyclic OSKM ameliorated disc-degeneration/senescence measures with HK2 and cytoskeletal changes.

Does not show: The examined abstract does not fully specify recipient species or all functional endpoints; degenerative-disc models are not systemic human healthspan and marker/energy effects do not prove safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[42] Conserved Partial Reprogramming Effects on the Methylome.

Shows: An original secondary analysis of five public methylation datasets found a small conserved set of reprogramming-associated CpGs across systems.

Does not show: Reanalysis shares its input experiments and is not five new trials or functional clinical validation; conserved CpGs do not establish necessary aging mediators.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[43] Development of an epigenetic clock resistant to changes in immune cell composition.

Shows: Immune-subtype comparisons showed clocks measure composition and intrinsic age; IntrinClock reduces composition dependence and responds to senescence/reprogramming.

Does not show: A corrected marker can improve measurement without proving intervention clinical benefit or safety; bulk-cell composition is a concrete alternative to years-reversed claims.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[44] Epigenetic reprogramming periosteum promotes aging critical segmental bone defect repair via methylation remodeling.

Shows: Juvenile-vesicle periosteal scaffolds improved old-mouse bone repair with methylation/osteogenic changes.

Does not show: A distinct material/vesicle intervention with mechanical and immune coeffects is not OSK therapy or isolated epigenetic causality; tissue repair does not prove general human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[45] Partial Reprogramming Exerts a Rejuvenating Effect on Human Mesenchymal Stem Cells That Underwent Replicative Senescence in Culture.

Shows: Sendai-OSKM improved cultured human-MSC senescence features and conditioned-medium wound activity but viral residues caused erythrocyte agglutination.

Does not show: Culture rejuvenation does not establish safe human therapy; the measured residue-related adverse assay contradicts inference from normal markers alone.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[46] Diverse partial reprogramming strategies restore youthful gene expression and transiently suppress cell identity.

Shows: Single-cell factor-subset screens restored youthful expression and transiently suppressed murine somatic identity with partly separable effects.

Does not show: Factor/identity heterogeneity is mechanistically useful but not adult-human clinical benefit; youthful expression does not ensure identity never changes or no tumor risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[47] Cognitive rejuvenation in old rats by hippocampal OSKM gene therapy.

Shows: Thirty-nine-day hippocampal OSKM in old female rats improved selected cognition versus old vector controls with marginal clock rejuvenation.

Does not show: A specific sex, brain delivery and brief pathology follow-up do not establish human healthspan or long-term tumor safety; function and clock significance need not move together.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4, SC5.

[48] Comparative analysis of mouse strains for in vivo induction of reprogramming factors.

Shows: Comparative reprogrammable-mouse strain and organ-exclusion work addressed identity loss, weight decline and premature death under continuous OSKM.

Does not show: Delivery/strain restriction can mitigate but cannot prove broadly safe human systemic treatment; continuous versus cyclic settings remain distinct causal boundaries.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[49] Deciphering the roadmap of in vivo reprogramming toward pluripotency.

Shows: Single-cell pancreas mapping identifies dedifferentiation intermediates and nonresponding stress states during OSKM induction across tissues.

Does not show: A reprogramming-state roadmap is not clinical aging reversal; state markers and cell selection do not by themselves establish safe retained identity or functional benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[50] Convergence of aging- and rejuvenation-related epigenetic alterations on PRC2 targets.

Shows: Skin methylome and histone profiling of partially reprogrammed mice showed enrichment at PRC2 targets and heterochromatin boundaries.

Does not show: Mark enrichment and shared physiological-aging samples do not establish PRC2 necessity, a new lifespan causal unit or human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[51] Epigenetic brain reprogramming rejuvenates neuro-immune circuits to reverse Alzheimer's disease pathology and systemic bone loss.

Shows: Brain-restricted OSK in APP/PS1 mice improved cognition/AD pathology and bone measures with Tet2 and extracellular-vesicle links.

Does not show: Forced disease models and restricted delivery are not human AD or healthy-aging trials; downstream factor dependence does not uniquely establish epigenetic age as mediator.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[52] AKG-TET axis is central to senescence plasticity.

Shows: Genetic/pharmacological TET and AKG manipulations bidirectionally changed human-cell senescence/resilience phenotypes.

Does not show: Cellular stress resistance and senescence markers are not human healthspan; this different node can have pleiotropic effects and does not establish OSK clinical causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[53] Mesenchymal stem cell derived extracellular vesicles reverses neural aging via OSKM modulation.

Shows: Human placenta-MSC infusion in old female mice altered neural aging pathways, with fetal-neural-cell vesicle/OSKM leads.

Does not show: Human donor cells are not human recipients; mixed vesicle and cell factors plus inferred OSKM modulation do not prove that partial reprogramming is necessary for benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[54] An epigenetic biomarker of aging for lifespan and healthspan.

Shows: DNAm PhenoAge development and validation improved prediction of mortality, function and selected aging-related outcomes.

Does not show: Clinical training targets and predictive validation are not causal intervention surrogacy; lowering a trained score need not cause better function or safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[55] A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.

Shows: NR in 20 older MCI adults increased NAD and selected clock measures changed, while cognition remained stable.

Does not show: Exploratory methylation and uncorrected CBF comparisons do not establish healthspan; drug exposure differs from reprogramming and illustrates marker/function dissociation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[56] Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA.

Shows: MESA clocks predicted selected incident cardiovascular outcomes with disease-context differences over follow-up.

Does not show: Prognostic association, sparse event subtypes and CAC interaction are not proof that induced clock reversal mediates fewer events or predicts gene-therapy safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[57] A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking.

Shows: Technical clock-replicate noise reached several years and principal-component clock retraining improved reliability.

Does not show: Improved analytical repeatability is not clinical surrogate validation; apparent year reversal can reflect measurement noise rather than actual healthspan gain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[58] Evaluation of short-term epigenetic age fluctuation.

Shows: Repeated blood samples from two men showed large short-term clock fluctuation, partly persisting after cell-composition adjustment.

Does not show: Tiny descriptive series does not invalidate every clock but prevents treating short marker excursions as proven clinical aging reversal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[59] Unveiling the epigenetic impact of vegan vs. omnivorous diets on aging: insights from the Twins Nutrition Study (TwiNS).

Shows: Eight-week diet-assigned twin comparison found selected blood clock changes with differing calorie intake.

Does not show: A short diet study is not partial reprogramming; methylation surrogates and energy differences do not establish clinical years regained or safe gene therapy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[60] A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors.

Shows: An intrinsic-capacity-trained blood clock predicted mortality and correlated with function in independent cohorts.

Does not show: Training on function supports prognosis but risks circular use as functional proof; prospective intervention-mediated function and tumor safety were not established.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[61] In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.

Shows: Cyclic OSKM extended progeroid-mouse life and improved selected older wild-type injury/metabolic recovery outcomes.

Does not show: Premature-aging genotype and recovery endpoints differ from normal human clinical healthspan; full identity/tumor safety and unique epigenetic aging mediation are not established by this abstract.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[62] Reprogramming in vivo produces teratomas and iPS cells with totipotency features.

Shows: Transient four-factor induction in mice generated multi-organ teratomas and pluripotent/totipotent-like cells.

Does not show: This full-reprogramming paradigm identifies a real delivery/state hazard but does not prove every controlled partial OSK regimen causes tumors or quantify human risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[63] Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state.

Shows: Full pluripotent reprogramming of senescent/centenarian human cells reset telomeres and several physiology measures, followed by redifferentiation.

Does not show: Passing through pluripotency and losing identity differs from partial identity-preserving treatment; donor age does not make this a clinical centenarian recipient study.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[64] AAVvector-mediated in vivo reprogramming into pluripotency.

Shows: AAV factor delivery produced mouse teratomas and circulating iPS cells, including full reprogramming without c-Myc and detectable vector integration.

Does not show: Removing c-Myc alone did not prevent full plasticity in this regime; delivery, integration and expression duration differ from later controlled partial systems, so hazard cannot be generalized indiscriminately.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[65] In vivo reprogramming leads to premature death linked to hepatic and intestinal failure.

Shows: Continuous OSKM caused mouse hepatic/intestinal dysfunction and early death; organ-exclusion strain design attenuated toxicity with molecular-age change.

Does not show: The actual continuous exposure differs from beneficial cyclic/tissue-targeted regimes; lower toxicity and markers are not proof of comprehensive safety or human healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[66] Initiation phase cellular reprogramming ameliorates DNA damage in the ERCC1 mouse model of premature aging.

Shows: Enhanced partial factors/small molecules in ERCC1 progeroid mice improved DNA-repair measures and clock state, with selected ALK2/5 inhibition phenocopy.

Does not show: Forced genotype, combined exposure and molecular endpoints do not establish natural adult-human benefit, lifespan or a unique Yamanaka-specific necessary mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[67] Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming.

Shows: Controlled neural factors altered developmental cortical expansion and separately prevented selected adult 5xFAD cognitive/pathology decline.

Does not show: Embryonic effects cannot be credited as adult aging reversal; identity perturbation, developmental programming and prophylactic disease-model treatment remain separate from adult human clinical healthspan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4, SC5.

[68] Natural killer cells act as an extrinsic barrier for in vivo reprogramming.

Shows: NK-cell transfer/depletion bidirectionally altered in vivo reprogramming, and NK cells killed intermediate reprogrammed states.

Does not show: Removing an immune barrier can favor plasticity while undermining surveillance; more reprogramming or larger organoids do not establish safely rejuvenated humans.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[69] Senescence promotes in vivo reprogramming through p16INK4a and IL-6.

Shows: Genetic p16/p53/p21/IL6 contrasts and sex/age observations identified context-dependent mouse senescence support for OSKM reprogramming.

Does not show: Shares the earlier senescence/reprogramming research platform; damage and immune permissiveness differ from safely controlled anti-aging treatment and do not establish human clinical function.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• partial-reprogramming-human-aging.review.md
• partial-reprogramming-human-aging.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 69 · load-bearing claims: 75 · verified: 75 · unverified: 0 · contradicted: 0 · schema 5.3